Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
tQjxB2r3eyFpsNVW
